Case series highlights potential cumulative pulmonary risk with ocrelizumab on: April 14, 2026, 09:08:51 pm #1 From NeurologyLive (April 8, 2026)--"Case series highlights potential cumulative pulmonary risk with ocrelizumab":https://www.neurologylive.com/view/case-series-highlights-potential-cumulative-pulmonary-risk-ocrelizumab Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
